Could Harnessing Natural Killer Cell Activity Be a Promising Therapy for Prostate Cancer?
Could Harnessing Natural Killer Cell Activity Be a Promising Therapy for Prostate Cancer?
复制标题
DOI：
10.1615/critrevimmunol.2021037614
复制
发表时间：
2021
影响因子：
1.3
通讯作者：
Wu J
中科院分区：
文献类型：
--
作者：
Wu J
利用自然杀伤（NK）细胞活性，无论是内源性NK还是基于NK细胞的治疗，都是许多肿瘤类型的前沿发展。有令人信服的临床证据表明，NK细胞活性的丧失与前列腺癌（PCa）疾病进展到致死性表型转移性去势抵抗性PCa （mCRPC）的显著相关性。鉴于mCRPC通常被认为是一种“冷”肿瘤，并且对免疫检查点阻断治疗仅引起边际反应以恢复CD8 T细胞活性，NK细胞靶向治疗可能提供了一个可行的机会，不仅可以直接靶向mCRPC，还可以“激活”冷的mCRPC肿瘤。然而，目前利用NK细胞活性治疗mCRPC的努力非常有限，只有一个开放的基于NK细胞的临床试验。本文将介绍NK细胞活性在控制转移性前列腺癌中的临床意义，并为利用NK细胞活性治疗mCRPC提供观点。
Harnessing natural killer (NK) cell activity, either endogenous NK or NK-cell-based therapy, is in the forefront development for many tumor types. There are compelling clinical evidence demonstrating the significant relevance of loss of NK cell activity with prostate cancer (PCa) disease progression to the lethal phenotype, metastatic castration-resistant PCa (mCRPC). Given that mCRPC is generally regarded as a “cold” tumor and has only elicited marginal response to immune checkpoint blockade therapy to revive CD8 T cell activity, NK cell targeted therapy may present a viable opportunity not only to directly target mCRPC and also to “fire up” the cold mCRPC tumor. However, current efforts on harnessing NK cell activity for treating mCRPC is very limited with only one open NK-cell-based clinical trial. This minireview will present the clinical significance of NK cell activity in controlling metastatic PCa and provide perspectives on harnessing NK cell activity for treating mCRPC.